SURVYR

TRAX

First Tracks Biotherapeutics, Inc.
$45.72
+$0.34 (0.75%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-23%+24%+70%+116%+163%Apr 2026Oct 2026Jul 202652w high $49.9152w low $14.72
TRAXSPY
Wall St. Highest PT $100.00 (+118.7%) Wall St. Avg PT $74.17 (+62.2%)
$15$37$59$81$103POC $19Hi $100Avg $74
Underwater Drawdown %Max DD -39.7%Current -4.6%
0.0%-39.7%
Relative Strength vs SPY+122.8% vs SPYOutperforming
+159%0%-159%
1W
+$2.95 (6.90%)
1M
+$9.07 (24.75%)
3M
+$3.85 (9.20%)
6M
+$22.08 (93.40%)
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
12 analysts · mean score 1.25
1 = Strong Buy · 5 = Sell
Strong Buy975%
Buy325%
Hold00%
Underperform00%
Sell00%
Wall Street consensus · as of Oct 19, 2026
Analyst price targets
Current price$45.72
Average target$74.17
+$28.45 (+62.2%) upsideaverage target vs current price
CurrentAverageMedian
Low$57.00
Median$70.00
High$100.00
12-month Wall Street target range · as of Oct 19, 2026
Recent analyst rating changes · 8
Reiterated
2026-10-16 · Leerink Partners reiterated Outperform on TRAX
Reiterated
2026-10-13 · Canaccord Genuity reiterated Buy on TRAX
Reiterated
2026-10-13 · Evercore ISI Group reiterated Outperform on TRAX
Reiterated
2026-10-13 · Wells Fargo reiterated Overweight on TRAX
Initiated
2026-09-30 · Canaccord Genuity started covering TRAX at Buy
Initiated
2026-09-18 · Evercore ISI Group started covering TRAX at Outperform
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$1.5B
P/E (next 12 months, estimated)-11.5
52-week range$14.72 – $49.91
Dividend yieldNo dividend
Analyst consensusStrong Buy (12)
Average analyst price target$74.17 (+62%)

What they do

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for TRAX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

TRAX earningsNext report in 8 days
Next report
Thu Nov 5, 2026Time not confirmed
EPS consensus-$0.89 range -$1.01–-$0.63
Revenue consensus$0 8 analysts
Last 1 quarters · EPS vs estimate
Aug 12, 2026-$0.95est -$0.80−18.4%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 12:15:36 ET
26-08-0.950.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-06-30$0–
2025-03-31$0–

News & catalysts

More news
First Tracks Biotherapeutics Announces $200 Million Private Placement
MT Newswires · Oct 15
First Tracks Biotherapeutics Announces $200 Million Private Placement
GlobeNewswire · Oct 15
Top biotechnology stock pick from Guggenheim
Investing.com · Oct 14
7 Reasons First Tracks Biotherapeutics (TRAX) Looks Pricey Following ANB033 Trial Data
Simply Wall St. · Oct 13
First Tracks Biotherapeutics (TRAX) Stock Looks Rich Following Phase 1b Celiac Data
Simply Wall St. · Oct 13
Rating changes
Reiterated
2026-10-16 · Leerink Partners reiterated Outperform on TRAX
Reiterated
2026-10-13 · Canaccord Genuity reiterated Buy on TRAX
Reiterated
2026-10-13 · Evercore ISI Group reiterated Outperform on TRAX
Reiterated
2026-10-13 · Wells Fargo reiterated Overweight on TRAX
Initiated
2026-09-30 · Canaccord Genuity started covering TRAX at Buy
Initiated
2026-09-18 · Evercore ISI Group started covering TRAX at Outperform

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Ware J. Anthony
Director · 2026-09-02
Sell
$1.8M
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-21 12:15:36 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026